Association of LAPTM4B gene polymorphism with breast cancer susceptibility

Cancer Epidemiology

Volumn 36, Issue 4, 2012, Pages 364-368

  Fan, Meirong ^a   Liu, Ye ^a   Zhou, Rouli ^b   Zhang, Qingyun ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Breast cancer; LAPTM4B; Polymorphism; Susceptibility

Indexed keywords

LYSOSOME ASSOCIATED MEMBRANE PROTEIN; LYSOSOME ASSOCIATED PROTEIN TRANSMEMBRANE 4 BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BASE SEQUENCE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 84863445647     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2011.12.004     Document Type: Article

References (31)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. Cancer J Clin 2010, 60:277-300.
2. Boyle P., Levin B. World Cancer Report 2008 2008, International Agency for Research on Cancer Press, Lyon.
3. Anderson B.O., Jakesz R. Breast cancer issues in developing countries: an overview of the Breast Health Global Initiative. World J Surg 2008, 32:2578-2585.
4. Sgroi D.C., Teng S., Robinson G., LeVangie R., Hudson J.R., Elkahloun A.G. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 1999, 59:5656-5661.
5. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685.
6. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
7. Yu J.C., Ding S.L., Chang C.H., Kuo S.H., Chen S.T., Hsu G.C., et al. Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell cycle and ubiquitin ligase genes. Carcinogenesis 2009, 30(9):1562-1570.
8. Sun Y.Y., Zang Z.H., Xu X.H., Zhang Z.L., Zhong L., Zan W., et al. The association of SULT1A1 codon 213 polymorphism and breast cancer susceptibility: meta-analysis from 16 studies involving 23,445 subjects. Breast Cancer Res Treat 2011, 125(1):215-219.
9. Mavaddata N., Antonioua A.C., Eastonb D.F., Garcia-Closas M. Genetic susceptibility to breast cancer. Mol Oncol 2010, 4(3):174-191.
10. Qiu L.X., Yuan H., Yu K.D., Mao C., Chen B., Zhan P., et al. Glutathione S-transferase M1 polymorphism and breast cancer susceptibility: a meta-analysis involving 46,281 subjects. Breast Cancer Res Treat 2010, 121:703-708.
11. Liu J.J., Zhang J., Zhang N. Identification of new hepatocellular carcinoma related genes by fluorescent differential display. J Beijing Med Univ 2000, 32:411-414.
12. Zhang J., Liu J.J., Zhang N., Zhou R.L. Screening of novel hepatocellular carcinoma-associated genes. J Beijing Med Univ 2001, 33:54-57.
13. Zhang J., Liu J.J., Zhou R.L. Partial cloning of LHS Cdna and effect of its expression on behavior of hepatocellular carcinoma cells. J Beijing Med Univ 2000, 32(6):526-529.
14. He J., Shao G.Z., Zhou R.L. Effects of the novel gene, LAPTM4B, highly expression in hepatocellular carcinoma on cell proliferation and tumorigenesis of NIH3T3 cells. J Beijing Med Univ 2003, 35:348-352.
15. Zhou L., He X.D., Yu J.C., Zhou R.L., Xiong F.X., Qian Q., et al. Expression of LAPTM4B in gallbladder carcinoma cells: the role in invasive potential. Hepatogastroenterology 2010, 57:207-211.
16. Kasper G., Vogel A., Klaman I., Gröne J., Petersen I., Weber B., et al. The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett 2005, 224:93-103.
17. Liu X.R., Zhou R.L., Zhang Q.Y., Zhang Y., Shao G.Z., Jin Y.Y., et al. Identification and characterization of LAPTM4B encoded by a human hepatocellular carcinoma-associated novel gene. J Beijing Med Univ 2003, 35:340-347.
18. Deng L.J., Zhang Q.Y., Liu B., Zhou R.L. Relationship between LAPTM4B gene polymorphism and susceptibility of lung cancer. J Beijing Med Univ 2005, 37(3):302-305.
19. Liu Y., Zhang Q.Y., Qian N., Zhou R.L. Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. Ann Oncol 2007, 18:311-316.
20. Cheng X.J., Xu W., Zhang Q.Y., Zhou R.L. Relationship between LAPTM4B gene polymorphism and susceptibility of colorectal and esophageal cancers. Ann Oncol 2008, 19:527-532.
21. Sun L., Zhang Q.Y., Liu Y., Qian N. Relationship between LAPTM4B gene polymorphism and susceptibility of lymphoma. Cancer Res Prev Treat 2007, 34(4):245-248.
22. Meng F.L., Song H.T., Luo C., Yin M.Z., Xu Y., Liu H.X., et al. Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer 2011, 10.1002/cncr.25833.
23. Xu F., Paquette A.J., Anderson D.J., Charalambous A., Askew D.S. Identification of a cell type-specific silencer in the first exon of the His-1 gene. J Cell Biochem 2000, 76(4):615-624.
24. Shao G.Z., Zhou R.L., Zhang Q.Y., Zhang Y., Liu J.J., Rui J.A., et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 2003, 22(32):5060-5069.
25. Zhou L., He X.D., Cui Q.C., Zhou W.X., Qu Q., Zhou R.L., et al. Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett 2008, 264:209-217.
26. Yang H., Xiong F.X., Lin M., Yang Y., Nie X., Zhou R.L. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 2010, 136(2):275-281.
27. Meng F.L., Yin M.Z., Song H.T., Yang H., Lou G., Zhou R.L. LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer 2010, 20(5):745-750.
28. Yang Y., Yang H., Mcnutt M.A., Xiong F.X., Nie X., Li L., et al. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep 2008, 20(5):1077-1083.
29. Zhou L., He X.D., Yu J.C., Zhou R.L., Yang H., Qu Q., et al. Overexpression of LAPTM4B promotes growth of gallbladder carcinoma cells in vitro. Am J Surg 2010, 199(4):515-521.
30. Li Y., Zou L.H., Li Q.Y., Haibe-Kains B., Tian R.Y., Li Y., et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010, 16:214-218.
31. Li L., Wei X.H., Pan Y.P., Li H.C., Yang H., He Q.H., et al. LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 2010, 29:5785-5795.